Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma

Ibrutinib, a bruton’s tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaohong, Wang, Michelle Y., Jiang, Huijuan, Lwin, Tint, Park, Paul M., Gao, Jing, Meads, Mark B., Ren, Yuan, Li, Tao, Sun, Jiao, Fahmi, Naima Ahmed, Singh, Satishkumar, Sehgal, Lalit, Wang, Xuefeng, Silva, Ariosto S., Sotomayor, Eduardo M., Shain, Kenneth H., Cleveland, John L., Wang, Michael, Zhang, Wei, Qi, Jun, Shah, Bijal D., Tao, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057695/
https://www.ncbi.nlm.nih.gov/pubmed/33730585
http://dx.doi.org/10.1016/j.celrep.2021.108870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057695/
https://www.ncbi.nlm.nih.gov/pubmed/33730585
http://dx.doi.org/10.1016/j.celrep.2021.108870

Ejemplares similares